Drug development approaches a fascinating era as the trend of digitalization introduces sophisticated technologies which can neutralize costly hazards faced in R&D pipelines, according to a new deep-dive report by Pharma IQ.
Intelligent enterprise technologies. including the likes of artificial intelligence and machine learning, are set to transform the pharmaceutical industry enabling better healthcare and drug discovery processes.
Almost 100 drug discovery practitioners from around the globe – including experts from leading companies such as Pfizer, Sanofi, Novartis, AstraZeneca and GSK – took part in our in-depth research. Key topics covered include:
- The IE applications that will have the most impact on businesses by 2020
- What stage businesses are on their AI journey and where they want to be by 2020
- The biggest challenges faced by organizations implementing IE and what can be done to overcome them
- Business readiness for investment in AI
- How IE technologies might impact pharma’s R&D phases
- Strategies for implementation
- And much more
Download this report for its exclusive insights on the challenges, opportunities and potential impact intelligent enterprise technologies will bring to the industry.
Pharma IQ takes a look at some of the trends forecasted to take hold this year: disruption for vendor landscapes, regulatory intervention and sophisticated analytics technologies gaining speed.
Muyinatu Bell Shares Top Recommendations for Implementing Artificial Intelligence & Machine Learning Solutions
In this keynote speaker spotlight, Muyinatu Bell shares her top recommendations for healthcare innovators implementing artificial intelligence and machine learning solutions. She also shares her thoughts on being selected by MIT Technology Review as one of 35 Innovators Under 35 in 2016, her thoughts on the next generation of healthcare, how intelligent automation technologies helped inspire her to develop innovative biomedical solutions, and what she hopes attendees will learn from her keynote session.
Leveraging RPA for the Business via Outsourcing Collaboration by Shuchita Singh, Director - Outsourcing Governance, AbbVie
An enterprise-wide Intelligent Automation CoE is an effective way to roll-out automation across various business lines, but the absence of such a central function requires creative approaches to harness automation. Through this Case Study, we will discuss:
- Why RPA was required to advance business function
- What was the optimal approach in the absence of a fully-functional Intelligent Automation CoE
- How to leverage third-party relationships to advance the approach
Companies of all types are leveraging intelligent automation to not only boost efficiency, but to help power their digital transformations—to innovate better, boost customer service and satisfaction, empower employees, and increase revenues and profits. As pharmaceutical firms work to close the gap between rising R&D costs and profits in an environment of increasing regulatory control and testing, Intelligent Automation (i.e. RPA, Cognitive Computing, AI, etc.) is expected to become a key enabler of increased profitability over the next decade. In this interactive infographic, we outline the top 5 ways Intelligent Automation is transforming the life sciences industry:
- Warehousing & Distribution
- Operational Excellence
- Data Management
- Personalized & Specialized Medicine
To receive this report via email, please contact us at email@example.com with "Content Request: Interactive Report: Top 5 Ways Intelligent Automation is Transforming Pharmaceutical Manufacturing" in the subject line.